No differences were observed across the AR101 group and the placebo group with respect to clinical characteristics (including past or present asthma) as discussed in Table 1. I am curious as to whether this was an expected finding, and if there was adequate power to assess efficacy and adverse event rates across different patient cohorts? I imagine a post-marketing study would help to delineate mediators of efficacy as well.
Easy one-click social registrationIs this safe?
We only receive the minimum information necessary to verify your account. We never get access to your friends/contacts or your profile, and we never post on your behalf. Your social account is used for logging in only.ORRegister via email
Send me updates on this Contest
In order to ensure a fair voting process and to make sure that no one votes more than once, we ask that you register either with a social networking account (easiest, only requires one click) or by registering with your email address (this will require you to click on a verification email that we will send you).
You only need to register once.